Cabio Biotech Wuhan Co Ltd
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.
Cabio Biotech Wuhan Co Ltd (688089) - Total Liabilities
Latest total liabilities as of September 2025: CN¥183.42 Million CNY
Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has total liabilities worth CN¥183.42 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cabio Biotech Wuhan Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Cabio Biotech Wuhan Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cabio Biotech Wuhan Co Ltd Competitors by Total Liabilities
The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hyliion Holdings Corp.
NYSE MKT:HYLN
|
USA | $12.38 Million |
|
Rainbow Tours SA
WAR:RBW
|
Poland | zł910.82 Million |
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
China | CN¥301.66 Million |
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
China | CN¥289.08 Million |
|
Fox-Wizel Ltd
PINK:FXWZF
|
USA | $7.38 Billion |
|
TRANSILVANIA INVESTMENTS ALLIANCE S.A.
RO:TRANSI
|
Romania | RON160.02 Million |
|
VIKRAM SOLAR LIMITED
NSE:VIKRAMSOLR
|
India | ₹18.59 Billion |
|
Texas Ventures Acquisition III Corp
NASDAQ:TVA
|
USA | $15.15 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Cabio Biotech Wuhan Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cabio Biotech Wuhan Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cabio Biotech Wuhan Co Ltd (2013–2024)
The table below shows the annual total liabilities of Cabio Biotech Wuhan Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥117.27 Million | -0.28% |
| 2023-12-31 | CN¥117.60 Million | -36.69% |
| 2022-12-31 | CN¥185.77 Million | +178.61% |
| 2021-12-31 | CN¥66.68 Million | +12.44% |
| 2020-12-31 | CN¥59.30 Million | +22.89% |
| 2019-12-31 | CN¥48.26 Million | -12.25% |
| 2018-12-31 | CN¥54.99 Million | +31.01% |
| 2017-12-31 | CN¥41.98 Million | -43.41% |
| 2016-12-31 | CN¥74.17 Million | -13.35% |
| 2015-12-31 | CN¥85.60 Million | +106.19% |
| 2014-12-31 | CN¥41.52 Million | +4.62% |
| 2013-12-31 | CN¥39.68 Million | -- |